The Asia Pacific Motion Sickness Treatment Market should witness market growth of 3.9% CAGR during the forecast period (2023-2029).
The market should expand as a result of the growing demand for medications that may successfully alleviate the symptoms of motion sickness. This condition is a typical hazard that is connected with extensive foreign travel. In addition, research has found that there is a gender difference in the frequency of motion sickness symptoms in virtual reality (VR), with females experiencing more symptoms than males do. This is because females tend to be more sensitive to motion sickness than males.
The considerable prevalence of motion sickness, particularly among females, is the reason for the projected rise in the demand for anticholinergic and antihistamines medications that inhibit emetic H1-receptors from preventing motion sickness. This is due to the fact that these treatments prevent emetic H1-receptors from activating. Because of this, it is anticipated that the growth of the market will accelerate throughout the time in question.
Moreover, the increasing emphasis of the enterprise on introducing merchandise that addresses and minimizes motion sickness indications is also bolstering market expansion. Introducing a cutting-edge waterproof wearable therapeutic device that provides user-controlled therapy for a range of nausea and vomiting conditions, including those caused by doctor-diagnosed migraines, morning sickness from alcohol withdrawal, anxiety, pregnancy, motion sickness, chemotherapy, and post-operative nausea.
India boasts many natural, historical, cultural, and spiritual treasures. India's spiritual grandeur and heritage attract millions of local and foreign tourists who seek to experience them. Links to sacred or historic locations, people, or events have been instrumental in the growth of several popular tourist destinations, with religion, spirituality, and legacy being significant motivators for travel.
To fully realize the potential of pilgrimage and heritage tourism in India, authorities are striving to integrate development plans for the chosen pilgrimage destinations and heritage cities in collaboration with other stakeholders. Due to these factors, the travel industry in the APAC region is expected to experience growth, and with the rise in tourism, people suffering from motion sickness are expected to increase, which will provide market growth for motion sickness treatment in the region.
The China market dominated the Asia Pacific Motion Sickness Treatment Market by Country in 2022; thereby, achieving a market value of $37.4 Million by 2029. The Japan market is poised to grow at a CAGR of 3.3% during (2023-2029). Additionally, The India market would showcase a CAGR of 4.6% during (2023-2029).
Based on Drug Class, the market is segmented into Antihistamines, Anticholinergics and Others. Based on Route of Administration, the market is segmented into Oral and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG, Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Prestige Consumer Healthcare, Inc., WellSpring Pharmaceutical Corporation (Avista Capital Partners).
The market should expand as a result of the growing demand for medications that may successfully alleviate the symptoms of motion sickness. This condition is a typical hazard that is connected with extensive foreign travel. In addition, research has found that there is a gender difference in the frequency of motion sickness symptoms in virtual reality (VR), with females experiencing more symptoms than males do. This is because females tend to be more sensitive to motion sickness than males.
The considerable prevalence of motion sickness, particularly among females, is the reason for the projected rise in the demand for anticholinergic and antihistamines medications that inhibit emetic H1-receptors from preventing motion sickness. This is due to the fact that these treatments prevent emetic H1-receptors from activating. Because of this, it is anticipated that the growth of the market will accelerate throughout the time in question.
Moreover, the increasing emphasis of the enterprise on introducing merchandise that addresses and minimizes motion sickness indications is also bolstering market expansion. Introducing a cutting-edge waterproof wearable therapeutic device that provides user-controlled therapy for a range of nausea and vomiting conditions, including those caused by doctor-diagnosed migraines, morning sickness from alcohol withdrawal, anxiety, pregnancy, motion sickness, chemotherapy, and post-operative nausea.
India boasts many natural, historical, cultural, and spiritual treasures. India's spiritual grandeur and heritage attract millions of local and foreign tourists who seek to experience them. Links to sacred or historic locations, people, or events have been instrumental in the growth of several popular tourist destinations, with religion, spirituality, and legacy being significant motivators for travel.
To fully realize the potential of pilgrimage and heritage tourism in India, authorities are striving to integrate development plans for the chosen pilgrimage destinations and heritage cities in collaboration with other stakeholders. Due to these factors, the travel industry in the APAC region is expected to experience growth, and with the rise in tourism, people suffering from motion sickness are expected to increase, which will provide market growth for motion sickness treatment in the region.
The China market dominated the Asia Pacific Motion Sickness Treatment Market by Country in 2022; thereby, achieving a market value of $37.4 Million by 2029. The Japan market is poised to grow at a CAGR of 3.3% during (2023-2029). Additionally, The India market would showcase a CAGR of 4.6% during (2023-2029).
Based on Drug Class, the market is segmented into Antihistamines, Anticholinergics and Others. Based on Route of Administration, the market is segmented into Oral and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG, Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Prestige Consumer Healthcare, Inc., WellSpring Pharmaceutical Corporation (Avista Capital Partners).
Scope of the Study
By Drug Class
- Antihistamines
- Anticholinergics
- Others
By Route of Administration
- Oral
- Others
By Distribution Channel
- Drug Store & Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Viatris, Inc.
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
- Baxter International, Inc.
- Novartis AG
- Abbott Laboratories
- Sun Pharmaceutical Industries Ltd.
- Zydus Lifesciences Ltd.
- Prestige Consumer Healthcare, Inc.
- WellSpring Pharmaceutical Corporation (Avista Capital Partners)
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Motion Sickness Treatment Market by Drug Class
Chapter 4. Asia Pacific Motion Sickness Treatment Market by Route of Administration
Chapter 5. Asia Pacific Motion Sickness Treatment Market by Distribution Channel
Chapter 6. Asia Pacific Motion Sickness Treatment Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Viatris, Inc.
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals, Inc.
- Baxter International, Inc.
- Novartis AG
- Abbott Laboratories
- Sun Pharmaceutical Industries Ltd.
- Zydus Lifesciences Ltd.
- Prestige Consumer Healthcare, Inc.
- WellSpring Pharmaceutical Corporation (Avista Capital Partners)
Methodology
LOADING...
